The impact of serum interleukin-17a as a predictive biomarker for neoadjuvant therapy response in breast cancer: a retrospective study

These findings highlight IL-17A as a dynamic biomarker modulated by NAT, with elevated levels indicating aggressive tumor behavior and resistance to therapy. The significant reduction of IL-17A in responsive patients, especially those with early-stage disease, underscores its potential utility in stratifying patients for personalized treatment. Further large-scale studies are warranted to validate its prognostic role and elucidate mechanisms linking IL-17A to chemoresistance and immune evasion in BC.